Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Terminated 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Dermatologic 1Classical hematology 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Hematologic Neoplasms 1Cytopenia 1Coronavirus Infections 1Carcinoma, Hepatocellular 1COVID-19 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Has results × HuMax-IL8 × Clear all
NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Bristol-Myers Squibb

Phase 1/2 Completed
281 enrolled 44 charts
Dermatologic

Melanoma, Neoplasms

NCT04050462 2025-10-16

Nivolumab Combined With BMS-986253 in HCC Patients

NYU Langone Health

Phase 2 Terminated
13 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT05148234 2025-09-30

BMS-986253 in Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
2 enrolled 11 charts
Classical hematologyMyeloid

Cytopenia, Myelodysplastic Syndromes

NCT04347226 2025-05-22

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Columbia University

Phase 2 Terminated
43 enrolled 14 charts
Other hematologic neoplasm

COVID-19, Coronavirus Infections, Hematologic Neoplasms

NCT03689699 2025-04-29

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Columbia University

Phase 1/2 Active not recruiting
59 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡